Physician profile
Robert D Rowe
NPI 1215240486
$1,898.22
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,829 · 2022: $69.18.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $601.91 | 2021 | |
| Glaxosmithkline, LLC. | $434.39 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $154.87 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.92 | 2021 | |
| Genzyme Corporation | $121.62 | 2021 | |
| Merck Sharp & Dohme LLC | $78.94 | 2021 | |
| Biocryst US Sales Co., LLC | $48.69 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.35 | 2021 | |
| Novartis Pharmaceuticals Corporation | $34.46 | 2021 | |
| Genentech USA, INC. | $34.15 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $34.06 | 2021-2022 | |
| Abbvie INC. | $28.92 | 2021 | |
| Pfizer INC. | $26.34 | 2021 | |
| Viiv Healthcare Company | $24.01 | 2021 | |
| Sanofi-Aventis U.S. LLC | $22.65 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.17 | 2021 | |
| Optinose US, INC. | $17.31 | 2021 | |
| Octapharma USA, INC. | $16.32 | 2021 | |
| Bio Products Laboratory USA, INC. | $15.74 | 2021 | |
| Pharming Healthcare, INC. | $13.40 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.